TY  - CHAP
AU  - Schäfer, Thomas
AU  - Özalp, Veli C.
AU  - Özalp, Veli C.
AU  - Schäfer, Thomas
AB  - Drug delivery systems traditionally relied on passive diffusion mechanisms for targeting and releasing of therapeutically active molecules. The major problems associated with    traditional delivery are poor specificity and dose-limited toxicity. Nanoparticles have found    applicability in the development of novel drug delivery systems by easily overcoming    toxicity problem. However, specificity of delivery has remained as a challenge.    Developments in the methods of reaching to targeted tissue have lead to new and improved    drug delivery platforms. Recently, active targeting has been incorporated by cell specific    ligands such as antibodies, lectins, growth factor receptors. More recently, aptamers gained    popularity in construction of novel actively targeted drug delivery systems (Ozalp et al.,    2011). Considerable proportions of aptamer-based delivery systems have been incorporated    to a variety of nanomaterials in order to improve their specific targeting properties (Chen et    al., 2011; Zhou et al., 2011).
DO  - 10.5772/35188
ID  - OAPEN ID: 612587
ID  - OAPEN ID: OCN: 1030822012
KW  - drug delivery
KW  - nanoparticles
KW  - drug delivery
KW  - nanoparticles
KW  - Aptamer
KW  - Protein
L1  - https://library.oapen.org/bitstream/id/5acda5c3-c5c0-4233-9002-4386044f93cd/612587.pdf
LA  - English
LK  - http://library.oapen.org/handle/20.500.12657/32346
PB  - InTechOpen
PY  - 2012
TI  - Chapter 7 Aptamer-Nanoparticle Bioconjugates for Drug Deliverynull
ER  - 
